FindTrial
Sign In

Serum Helicobacter antibody level according to the antibody producibility

Does the antibody producibility affect serum anti-Helicobacter pylori immunoglobulin G antibody titer?

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0001302
Enrollment
400
Registered
2014-12-08
Start date
2014-11-11
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Konkuk University Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: With H. pylori infection (=positive Giemsa staining) Underwent serum pepsinogen (PG) assay, anti-H. pylori IgG antibody test, hepatitis B virus surface antigen (HBsAg)/antibody test using the same sample Endoscopic biopsy for H. pylori evaluation on the same day

Exclusion criteria

Exclusion criteria: under 20 years old positive HBsAg finding recent history of medication immunocompromised state

Design outcomes

Primary

MeasureTime frame
degree of H. pylori infiltration on gastric biopsy—

Secondary

MeasureTime frame
serum hepatitis B virus surface antibody (HBsAb) titer;serum anti-Helicobacter pylori immunoglobulin G antibody titer—

Countries

Korea, Republic of

Contacts

Public ContactSun-Young Lee

Konkuk University Medical Center

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026